analysis, the economics of health care, medical ethics, and other related professions. Each panel is composed of a chairperson, voting members, a nonvoting consumer representative, and a nonvoting industry representative.

Current Members of the Panel

Thomas V. Holohan, MA, MD, FACP (Chairperson); Leslie P. Francis, JD, Ph.D.; Judith A. Cahill, MA; Michael L. Friedland, MD; Kathy J. Helzlsouer, MD, MHS; Robert C. Johnson, MS; Ronald P. Jordan, R.Ph.; Mitchell Sugarman, MBA, MS; Cathleen M. Dooley, MPA; and Christine M. Grant, JD.

Topic of the Meeting

The Panel will discuss presentations from interested persons regarding the combination of high dose chemotherapy and stem cell transplantation for the treatment of multiple myeloma.

Procedure and Agenda

The Panel will hear oral presentations from the public for approximately 90 minutes on each day of the meeting. The Panel may limit the number and duration of oral presentations to the time available. If you wish to make a presentation during one of these sessions, you must submit the following to the Executive Secretary before the Deadline for Presentation Submissions date listed in the Dates section of this notice: a brief statement of the general nature of the evidence or arguments you wish to present, the names and addresses of proposed participants, and an estimate of the time required to make the presentation. We will request that you declare at the meeting whether or not you have any financial involvement with manufacturers of any items or services being discussed (or with their competitors).

After the 90-minute public presentation on Day 2 of the meeting, we will make a presentation to the Panel. After our presentation, the Panel will deliberate openly on the topic. Interested persons may observe the deliberations, but the Panel will not hear further comments during this time except at the request of the chairperson. At the end of the Panel deliberations, the Panel will allow a 30-minute open public session for any attendee to address issues specific to the topic.

Submission of Final Comments

Interested persons not scheduled to make an oral presentation, unable to attend the meeting, or wishing to make further remarks, may submit written comments to the Executive Secretary by the Deadline for Submission of Final Comments in the Dates section of this notice.

HCFA Home Page

You may access detailed information regarding the agenda and schedule of presentations on our home page (www.hcfa.gov/quality/8b.htm) the day after the Deadline for Presentation Submissions in the Dates section of this notice.

Authority: 5 U.S.C. App. 2, section 10(a)(1) and (a)(2).

(Catalog of Federal Domestic Assistance Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: August 9, 1999.

Michael M. Hash,

Deputy Administrator, Health Care Financing Administration.

[FR Doc. 99–20988 Filed 8–12–99; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: A Basal Cell Carcinoma Tumor Suppressor Gene

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: U.S. Patent Application Serial No. 08/857,636 filed May 16, 1997 entitled ''A Basal Cell Carcinoma Tumor Suppressor Gene'', PCT application US97/08433 filed May 16, 1997 designating all countries, except the U.S., entitled, ''A Basal Cell Carcinoma Tumor Suppressor Gene'' to Ontogeny, Inc., having a place of business in Cambridge, MA. The United States of America is the assignee or the exclusive licensee of the patent rights in this invention.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 12, 1999.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to Richard U. Rodriguez, M.B.A., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 496–7056, ext. 287; Facsimile: (301) 402–0220; E-mail: rr154z@nih.gov.

SUPPLEMENTARY INFORMATION: In an effort to develop a method of detection and an efficacious treatment for basal cell carcinoma, nevoid basal cell carcinoma syndrome, and medulloblastoma, the inventors posit that the Basal Cell Carcinoma Tumor Suppressor Gene and the disclosed mutations thereof may play a key physiological role.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be limited to the fields of human diagnostics and therapeutics for indications consisting of nevoid basal cell carcinoma syndrome, basal cell carcinoma, and medulloblastoma and may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: August 6, 1999.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 99–20938 Filed 8–12–99; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Information Collections Submitted to the Office of Management and Budget for Approval Under the Paperwork Reduction Act

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of information collection; request for comments.

SUMMARY: The U.S. Fish and Wildlife Service (Service) has sent the collection of information described below to the Office of Management and Budget (OMB) for approval under the provisions of the Paperwork Reduction